AST Presents At ISPE Facilities of the Future Conference
The 2019 ISPE Facility of the Future Conference will explore what pharmaceutical manufacturing facilities will look like in the future and will feature presentations from various industry thought leaders and experts sharing current projects highlighting what these “facilities of the future” look like. New manufacturing challenges, technologies and regulator factors impact the ability of today’s companies to stay competitive and cost-effective. AST’s Josh Russell will be presenting on key challenges associated with fill-finish of cell and gene therapies and discussing real-world case studies where AST’s GENiSYS Lab and GENiSYS R systems are being used to overcome these hurdles.
Tacoma, WA – The 2019 ISPE Facilities of the Future Conference brings together industry experts and thought leaders to discuss and highlight successful solutions to pressing facility challenges facing the biopharma, cell and gene therapy manufacturers. This year’s conference will be held in San Francisco, CA. February 7th & 8th.
With cell and gene therapies demonstrating promising therapeutic outcomes for patients and gaining rapid approvals from the EU and FDA manufacturers are pioneering new and innovative paths to meet cGMP manufacturing requirements. AST is pleased to be among the many thought leaders presenting at the conference discussing the various challenges associated with the fill-finish of cell, gene and regenerative medicines. Drawing from successful projects, AST’s Josh Russell will highlight various case studies where AST’s GENiSYS Lab and GENiSYS R systems have solved many of these key challenges.
Discussing his presentations Russell states, “The goal of every manufacture is to successfully deliver high quality potentially life saving products to patients. The cell and gene therapy space is moving so quickly on so many fronts, with little regulatory guidance, that it is important to think with the big picture in mind early. Recognizing risks early in the development process and avoiding their shortcomings will allow manufacturers to efficiently and cost effectively produce a high-quality therapy for their patients. The insights given at this conference will give attendees an edge in understanding and will bring back tools that will have an immediate and meaningful impact”.
For additional information about the conference and the agenda click here.
